Navigation Links
VCU Massey Cancer Center researchers identify a new class of anti-cancer drugs based on platinum

Researchers at Virginia Commonwealth University's Massey Cancer Center have created a new platinum-based, anti-cancer agent able to overcome acquired drug resistance by first modifying the way it is absorbed into cancer cells and then attacking the DNA of those cancer cells.

The findings may help researchers design a new generation of anti-cancer drugs that selectively target cancer cells, reduce resistance and side effects and expand the range of tumors that can be treated by platinum.

In the Dec. 26 issue of the journal Inorganic Chemistry researchers reported on the design of a new trinuclear platinum compound and demonstrated that its cellular absorption is significantly greater than that of neutral cisplatin, as well as other multi-nuclear platinum compounds. The enhanced uptake into cancer cells takes advantage of weak molecular interactions on the cells' surface. These results underscore the importance of the new compound's "non-covalent" interactions, prior to the attack on DNA. Non-covalent interactions minimize potential side reactions and produce changes in the structure of proteins and DNA, which is different from currently used drugs. This research was selected as the cover article for the print version of the journal, Issue 26.

Researchers compared the cytotoxicity and cellular concentrations of three anti-cancer drugs including the phase II clinical drug, BBR 3464, cisplatin and the new trinuclear platinum compound. In a laboratory model, human ovarian cancer cells were exposed to each drug.

"In platinum antitumor chemistry our objective is to design and develop complexes acting by new mechanisms of action," said Nicholas Farrell, Ph.D., professor and chair in the Department of Chemistry at VCU, and lead author of the study. "Resistance to current drugs is due to poor cellular absorption and an increased ability of the cell to process or repair the damage caused by the chemotherapeutic agent."

"Our novel compou nd was designed to overcome resistance by emphasizing new modes of DNA binding, and in the process we have found that the amount of platinum drug entering cells is increased," he said. "The effectiveness of a platinum drug in killing cells is directly related to its concentration inside the cell."

DNA-damaging agents, such as cisplatin, are among the most effective classes of compounds in clinical use for the treatment of cancer. The principal function of cisplatin is to bind to DNA. Platinum drugs are the largest class of anti-cancer drugs in the clinic and the most important in terms of treatment. Cisplatin is a chemotherapy drug that is given for the treatment of metastatic testicular or ovarian cancers, and some advanced bladder cancer, and is a very effective drug in combination with other therapies.

However, according to Farrell, these current agents have limited activity against many common human cancers, and they are susceptible to acquired drug resistance. He added that resistance to cisplatin has become a clinically relevant issue ?especially for patients battling ovarian cancer because they develop resistance to cisplatin at a rapid rate.

Farrell said that use of the "non-covalent" approach and emphasizing cell uptake may help minimize the side effects of current platinum drugs. He said that both cell uptake and the ability of the cell to minimize the effect of DNA attack, or DNA repair, play a critical role in cellular resistance to cisplatin by altering its ability to effectively kill tumor cells. By understanding the features of cisplatin that contribute to resistance, Farrell and his team designed the new compound to circumvent these problems.


'"/>

Source:Virginia Commonwealth University


Related biology news :

1. Massey Cancer Center researcher helps to identify a piece of the cancer puzzle
2. VCU Massey Cancer Center study shows enzyme linked to spread of breast cancer cells
3. Massey researchers induce cell death in leukemia
4. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
5. Jump-starting T Cells In Skin Cancer
6. Deficient DNA Repair Capacity Associated With Increased Risk Of Breast Cancer
7. Fox Chase Cancer Center scientists identify immune-system mutation
8. Breakthrough Microarray-based Technology for the Study of Cancer
9. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
10. Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery
11. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/18/2016)... --> --> ... & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & Detection ... border security market and the continuing migration crisis in the ... has led visiongain to publish this unique report, ... defence & security companies in the border security ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... FL (PRWEB) , ... May 25, 2016 , ... Lady ... eight she tore her cruciate ligament in her left knee. Lady’s owner Hannah sought ... a central Florida board-certified veterinary surgeon, to repair her cruciate ligament and help with ...
(Date:5/24/2016)... ... May 24, 2016 , ... Cell ... injuries, will be accelerated by research at Worcester Polytechnic Institute (WPI) that yielded ... healing and tissue regeneration. , The novel method, developed by WPI faculty members ...
(Date:5/24/2016)... ... 24, 2016 , ... Last week, Callan Capital, an integrated wealth management firm ... Future of San Diego Life Science event at the Estancia La Jolla Resort and ... event with speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, and Faheem ...
(Date:5/23/2016)... , ... May 23, 2016 , ... The need for blood donations in South Texas ... by the South Texas Blood & Tissue Center, blood donations are on the decline. In ... and they are down 21 percent in South Texas in the last four years alone. ...
Breaking Biology Technology: